Company news
Precipio, Inc. news in 2023
Precipio, Inc.'s news releases, calls and decks from 2023, newest first.
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
December 13, 2023
Precipio Announces Q3-2023 Shareholder Update Call
November 15, 2023
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
October 17, 2023
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
October 2, 2023
Precipio Continues to Sign New HemeScreen™ Customers
September 27, 2023
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
September 24, 2023
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
September 20, 2023
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
September 12, 2023
Precipio Announces Q2-2023 Shareholder Update Call
August 9, 2023
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
August 7, 2023
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
August 2, 2023
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
July 31, 2023
Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
June 13, 2023
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
June 12, 2023
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
June 7, 2023
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
June 6, 2023
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
May 21, 2023
Precipio Shares Growth Catalysts For HemeScreen
May 16, 2023
Precipio Announces Q1-2023 Shareholder Update Call
May 14, 2023
Precipio Signs Another HemeScreen™ Customer
May 3, 2023
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
May 3, 2023
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
April 26, 2023
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
April 18, 2023
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
March 27, 2023
Precipio Ships First IV-Cell® Order to Major US Healthcare System
March 20, 2023
Precipio continues to sign up and onboard HemeScreen™ customers
March 6, 2023
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
February 13, 2023
Precipio Signs Another Major HemeScreen™ Customer
January 10, 2023